The bad news: Cancer did not take a break during the COVID-19 pandemic, and thousands of people had to forego or postpone cancer treatments and care due to the downstream effects of the virus. Preventive screenings and anti-cancer treatments were suspended to save hospital capacity and for fear of viral contagion. Nearly 1,000 cancer clinical trials were stalled. The good news: Innovations from the cancer community have boosted our understanding and approach to COVID-19. Novel applications of real-world data, use of oncology treatments with anti-COVID effect, trial innovations—these and other advances in oncology have influenced COVID-19 management. This panel of experts will discuss the current and potential long-term ramifications of COVID-19 for cancer care and research. A key challenge: How to leverage innovations in oncology to compensate for postponed research and treatments.